Dry and neovascular “wet” age-related macular degeneration: Upcoming therapies
The age-related macular degeneration (AMD) field is witnessing promising advancements in therapeutic options. Breakthrough drugs such as pegcetacoplan and avacincaptad have been FDA-approved for dry AMD, marking a significant development as there were no treatment options until August 2023. While se...
Saved in:
Main Authors: | Audrey Yan, Nasiq Hasan, Jay Chhablani |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
Series: | Indian Journal of Ophthalmology |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/IJO.IJO_1120_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A comprehensive review on early detection of drusen patterns in age-related macular degeneration using deep learning models
by: Kiruthika M, et al.
Published: (2025-02-01) -
Vitrectomy for full-thickness macular hole developed during aflibercept treatment for wet age-related macular degeneration
by: Agnieszka Nowosielska
Published: (2024-12-01) -
Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration
by: Anat Loewenstein, et al.
Published: (2024-12-01) -
Resveratrol Supplementation in Wet AMD: Association With Fewer Intravitreal Injections and Reduced Macular Fibrosis
by: Datseris I, et al.
Published: (2025-01-01) -
12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01)